1. What IND to Phase 1 Readout Actually Costs
The most cited number in biotech finance is also the most misapplied. Tufts CSDD / DiMasi et al. (Journal of Health Economics, 2016) pegs mean out-of-pocket Phase 1 cost at $25.3M per program (2013 USD) — inflated to 2025 dollars, that's approximately $32–34M. Add IND-enabling GLP tox and CMC carry-over and the full pre-FIH-to-readout envelope is routinely $40–55M for a single small molecule asset.
| Source | Phase 1 Cost Estimate | Notes |
|---|---|---|
| Tufts CSDD / DiMasi 2016 (JHE) | $25.3M mean (2013 $) → ~$33M (2025 $) | Industry survey; capitalized cost excluded |
| Tufts CSDD 2024 White Paper | $7,829/day | Based on 2016–2021 protocol data |
| Medidata / Industry (per-patient) | $136,783 avg. per pt; $5.26M total | 39-patient average cohort |
| NYU Stern / CBO (inflation-adj.) | ~$28M | Updated DiMasi, 2024 dollars |
| PMC / 2024 Meta-analysis | $117.4M mean full phase | Full pipeline; Ph1 is ~20% of that |
Therapeutic area variance is not noise — it is the model. Phase 1 trials in oncology with dose escalation cohorts, separate expansion arms, and PK/PD endpoints cost materially more than infectious disease or rare disease programs with smaller cohorts. The range is real: $300K (small, single-site SAD/MAD) to $3M+ per patient (complex oncology). CFOs who model off the median without therapeutic-area adjustment are not modeling their company — they are modeling the average of everyone else's.
- IPO to Phase 1 readout: 2–4 years. The 2023–2024 IPO cohort that priced with Phase 1 assets in progress is still waiting on readouts 18–30 months later
- Phase 1 FPI to primary completion: average ~2.0–2.5 years (BIO/Biomedtracker industry data); CFOs routinely model 12–15 months
- Median clinical-stage biotech cash at Phase 1 entry: $18–24M of runway — below the 24–30 months institutional investors now demand post-2022
- CRO pass-throughs: now 35–55% of total trial cost, with roughly 49% of multi-center trial budgets going to CRO-managed activities; pass-throughs are the least controlled line in any budget
The sharpest CFOs run two runway models in parallel. The base case assumes protocol on time, FPI by month 4 of enrollment activation, and CRO pass-throughs within contract. The slip case adds 6 months to every milestone, models a 20% pass-through overrun, and assumes one amendment cycle.
2. Pre-FIH Load: The 10–20% CFOs Routinely Miss
The cost envelope between IND submission and first-patient-in is where financial models most reliably fail. These costs live in "R&D expense" in internal reporting, get rolled up with discovery burn, and never get their own milestone flag.
| The Buried Cost Stack | Cost Range | What CFOs Miss |
|---|---|---|
| GLP tox (rodent + non-rodent) | $1–5M | Repeat-dose studies: 28-day rat $300–500K, 28-day dog $500–900K |
| GMP supply for FIH | $3–10M | Biologics/cell therapy at high end; contracted before IND is filed |
| CMC / drug product D&O | $1–3M | Manufacturing development costs not separated from clinical supply |
| Internal FTE carry (IND review) | $2–3M | 6–12 months of RA, medical, CMC staff while FDA clock runs |
| Regulatory + IND prep (external) | $1–3M | CRO regulatory fees, writing, eCTD assembly — treated as sunk |
The honest IND-filing-to-Phase-1-readout budget for a single clinical-stage asset is:
- - Small molecule: $40–55M
- - Biologic / cell therapy: $55–80M (adds $3–10M for biologics-specific GMP complexity)
These are not edge cases. These are the numbers from companies that actually ran trials. The IND-enabling GLP tox program alone for a biologic with non-human primate toxicology runs $2.5–5M and takes 15–20 months — a timeline and cost commitment made before FIH that most financial models treat as a prior-period item, not a draw on Phase 1 runway.
3. The $60M Biotech Scenario: What the Numbers Actually Say
Assume a single clinical asset, $60M cash at IND filing, and a competent team running a standard Phase 1 dose-escalation study. Here is what base case and slip case look like side by side.
| Base Case vs. Slip Case ($60M at IND) | Base Case | Slip Case (+6mo, 20% CRO overrun) |
|---|---|---|
| Month 0–12: IND review, FTE carry, GLP closeout | $7.5M | $7.5M |
| Month 2–18: Phase 1 enrollment + follow-up | $24.5M | $51.5M ($24.5M + $27M) |
| Phase 1 pass-through overrun (20% on 45% of CRO spend) | $0 | +$8.0M |
| GMP supply (Phase 1 clinical batch + stability) | $6.0M | $7.5M |
| Regulatory, data management, safety reporting | $4.0M | $5.5M |
| G&A + public company costs (if post-IPO, 24 months) | $8.0M | $10.0M |
| Contingency / protocol amendment | $5.0M | $8.0M |
| Total cash consumed | ~$55.0M | ~$98.0M |
| Cash remaining from $60M | ~$5.0M | ($38.0M) — structurally short |
| Real capital needed to reach readout | $65–70M | $100–125M |
The base case leaves $5M — not enough to run an end-of-Phase-1 meeting, write a Phase 2 protocol, or defend a partnership negotiation. The slip case is not a catastrophic scenario. Six months of slippage is the median, not the tail.
"$60M funded to readout" is structurally false at industry-norm timelines. The arithmetic does not close. A bridge round is not a failure — it is the statistical norm for any asset that experiences median slippage at median burn. A CFO not modeling this is not modeling reality; they are modeling the deck.
4. What a Sharp CFO Pulls Now
Five moves. No ceremony.
- 1. Rebuild total trial cost using Medidata 2023+ benchmark data. The Medidata Clinical Trial Financial Management (CTFM) dataset provides current fair market value benchmarks by procedure, therapeutic area, and geography. Any budget built off internal estimates or prior-CRO quotes older than 18 months is priced in a different market. Clinical trial costs are rising 5–7% annually. Reprice before the next board presentation.
- 2. Model two runways every quarter — base and slip — as a standing board deliverable. Base case: current timeline, current burn, no amendments. Slip case: +6 months, +20% pass-throughs, one protocol amendment cycle. The delta between them is the size of the bridge you are pre-negotiating. Running one model is operational; running two is financial governance.
- 3. Trigger bridge conversations at the 18-month runway mark — not the 12-month mark. The 2022–2026 biotech financing environment has lengthened close timelines. Institutional follow-ons that closed in 90 days in 2021 are taking 6–9 months in 2026. An 18-month trigger gives you room to run a process, not respond to an emergency. If your slip case shows 18-month runway in fewer than three quarters, the conversation starts now.
- 4. Write a 15% hard cap on pass-through overruns into CRO contract language. Pass-throughs now represent 35–55% of total trial cost and are the most variable line in any Phase 1 budget. Most CRO contracts allow unlimited pass-through escalation with sponsor notification. Change that. A 15% hard cap requires pre-approval for overruns beyond threshold and forces the CRO to flag early rather than true-up quarterly. This is not aggressive — it is standard in every well-negotiated MSA. If your CRO pushes back, that is information about how they intend to run your money.
- 5. Separate GMP supply from clinical development in internal reporting. They are different cost centers, different risk profiles, and — critically — eligible for different financing instruments. GMP supply is asset-backed and predictable; it can support royalty financing, non-dilutive im manufacturing credit, or a standalone CMO deal. Clinical development burn is milestone-dependent and dilutive. Running them together in a single "R&D expense" line obscures both the risk and the financing optionality. Split the P&L reporting. Split the forecasting model. Investors who understand the difference will ask — be ready to answer before they do.
- DiMasi et al., Journal of Health Economics, 2016 (Vol. 47, pp. 20–33) — Tufts CSDD Phase 1 out-of-pocket cost survey; $25.3M mean Phase 1 cost (2013 USD).
- Tufts CSDD, August 2024 White Paper (Therapeutic Innovation and Regulatory Science) — "Quantifying the Value of a Day of Delay in Drug Development"; Phase 1 direct cost $7,829/day; Phase III $55,716/day.
- Medidata Solutions, CTFM Benchmark Data / Fair Market Value (2023–2024) — Industry standard for per-procedure and per-patient cost benchmarking; basis for pass-through FMV analysis.
- regfo.com IND-Enabling Studies Cost Guide (2026) — Current GLP tox cost ranges: 28-day rat $300–500K; 28-day dog $500–900K; total small molecule IND-enabling tox $1.5–2.8M; biologic (NHP) $2.5–5.0M.
- IQVIA Institute, Global R&D Trends 2026* (March 2026) — Clinical development timeline elongation, pipeline concentration, regulatory pressure.
- FierceBiotech / JPM Q1 2026 Analysis (April 2026) — Early-stage biotech first-time financings on pace for worst year since pre-pandemic; close timeline elongation data.
- PMC / JAMA 2024 meta-analysis — Mean full clinical phase cost $117.4M per drug candidate; clinical stage 68% of total R&D cost.
- NYU Stern / CBO, 2024 — Phase 1 out-of-pocket ~$28M (inflation-adjusted DiMasi); Phase 2 $65M; Phase 3 $282M.
- abacum.ai Biotech Rolling Runway Analysis — 70% of biotech companies deplete funds within 18 months post-IPO without robust forecasting; industry standard 18–24 month runway minimum.
- k38consulting Biotech Forecasting Analysis (2025) — Biotech-specific runway requirements vs. standard startup models; 18–24 month minimum.
- Vision Life Sciences, Biotech IPO & Funding Landscape 2026* — IPO pipeline and close timeline data; 30–50 biotechs in confidential filing stage as of February 2026.